Lexology October 6, 2023
McDermott Will & Emery

The United States Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have further extended flexibilities that allow providers to prescribe controlled substances via telemedicine without first performing an in-person visit. The flexibilities were initially provided during the COVID-19 public health emergency (PHE). The extension runs through December 31, 2024.

The DEA anticipates releasing a final rule addressing telemedicine prescription of controlled substances in fall 2024.

In Depth

On October 6, 2023, the DEA and SAMHSA issued a temporary rule that will extend the full set of telemedicine flexibilities adopted during the PHE through December 31, 2024. This extension, which follows an earlier temporary rule issued in May 2023, authorizes all DEA-registered practitioners to prescribe...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Govt Agencies, HHS, Patient / Consumer, Provider, Technology, Telehealth
Related Articles:
Teladoc expands virtual sitter capabilities
AHA, others urge Congress to act on alternative payment models, avoid physician payment cut
Are telehealth visits for pediatric primary care associated with higher rates of health care utilization?
Hospital recovery at risk if Congress doesn’t extend telehealth, Fitch Ratings says
End of home health, telehealth coverage threatens hospitals' recovery: Fitch

Share This Article